Авторы

  • Шагазатова Б.X., Кудратова Н.А., Юлдашева Н.Х.

Ключевые слова:

ожирение, сахарный диабет 2 типа, медикаментозное и хирургическое лечение.

Библиографические ссылки

Cui H., Lopez M., Rahmouni K. The cellular and molecular bases of leptin and ghrelin resistance in obesity // Nat. Rev. Endocrinol. ‒ 2017. ‒ Vol. 13, №6. ‒ P. 338-351.

Davies M. J., Bergenstal R., Bode B. et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial // J.A.M.A. ‒ 2015. ‒ Vol. 314, №7. ‒ P. 687-699.

Deurenberg-Yap M., Schmidt G., van Staveren W. A. et al. The paradox of low body mass index and high body fat percentage among Chinese, Malays and Indians in Singapore // Int. J. Obes. Relat. Metab. Dis. ‒ 2000. ‒ Vol. 24, №8. ‒ P. 1011-1017.

Ding C., Chan Z., Magkos F. Lean, but not healthy: the 'metabolically obese, normal-weight' phenotype // Curr. Opin. Clin. Nutr. Metab. Care. ‒ 2016. ‒ Vol. 19, №6. ‒ P. 408-417.

Eisenberg D., Shikora S. A., Aarts E. et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery // Surg. Obes. Relat. Dis. ‒ 2022. ‒ Vol. 18, №12. ‒ P. 1345-1356.

Farr O. M., Sofopoulos M., Tsoukas M. A. et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial // Diabetologia. ‒ 2016. ‒ Vol. 59, №5. ‒ P. 954-965.

Flancbaum L. Mechanisms of weight loss after surgery for clinically severe obesity // Obes. Su rg. ‒ 1999. ‒ Vol. 9, №6. ‒ C. 516-523.

Florentin M., Liberopoulos E. N., Elisaf M. S. Sibutramine-associated adverse effects: a practical guide for its safe use // Obes. Rev. ‒ 2008. ‒ Vol. 9, №4. ‒ P. 378-387.

Forouzanfar M. H., Alexander L., Anderson H. R. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. ‒ 2015. ‒ Vol. 386, №10010. ‒ P. 2287-2323.

Gadde K. M., Pritham Raj Y. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice // Curr. Diab. Rep. ‒ 2017. ‒ Vol. 17, №5. ‒ P. 34.

Gallagher D., Heymsfield S. B., Heo M. et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index // Amter. J. Clin. Nutr. ‒ 2000. ‒ Vol. 72, №3. ‒ P. 694-701.

Gallagher D., Visser M., Sepúlveda D. et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? // Amer. J. Epidemiol. ‒ 1996. ‒ Vol. 143, №3. ‒ P. 228-239.

Garcia S. B., Barros L. T., Turatti A. et al. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen // Cancer Lett. ‒ 2006. ‒ Vol. 240, №2. ‒ P. 221-224.

Garvey W. T., Mechanick J. I., Brett E. M. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity // Endocrinol. Pract. ‒ 2016. ‒ Vol. 22, Suppl 3. ‒ P. 1-203.

Garvey W. T., Ryan D. H., Look M. et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topira-mate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study // Amer. J. Clin. Nutr. ‒ 2012. ‒ Vol. 95, №2. ‒ P. 297-308.